MCID: ANP005
MIFTS: 59

Anaplastic Astrocytoma

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anaplastic Astrocytoma

MalaCards integrated aliases for Anaplastic Astrocytoma:

Name: Anaplastic Astrocytoma 11 19 58 53 14 16 71 75
Astrocytoma, Anaplastic 28 5
Grade Iii Astrocytoma 11 19
Grade Iii Astrocytic Tumor 11

Characteristics:


Prevelance:

1-9/1000000 (United States) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3078
MeSH 43 D001254
NCIt 49 C9477
SNOMED-CT 68 55353007
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0334579
Orphanet 58 ORPHA251589
UMLS 71 C0334579

Summaries for Anaplastic Astrocytoma

Orphanet: 58 A rare, high-grade, malignant glial tumor, histologically characterized by abundance of pleomorphic astrocytes and multiple mitotic figures, often associated with diffuse infiltration of the surrounding tissue, considerable edema and mass effect and involvement of the contralateral brain. Depending on the primary localization of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), seizures, progressive neurological deficits, and/or behavioral changes. The tumor is most commonly localized in the frontal and temporal lobes, brain stem and spinal cord.

MalaCards based summary: Anaplastic Astrocytoma, also known as astrocytoma, anaplastic, is related to idh-mutant anaplastic astrocytoma and idh-wildtype anaplastic astrocytoma, and has symptoms including headache, seizures and motor manifestations. An important gene associated with Anaplastic Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Dabrafenib and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and eye, and related phenotypes are Reduced mammosphere formation and Decreased viability in pancreas lineage

GARD: 19 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders.

Disease Ontology: 11 A malignant astrocytoma that is characterized by cells with regular, round to oval nuclei.

Wikipedia: 75 Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the... more...

Related Diseases for Anaplastic Astrocytoma

Diseases related to Anaplastic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 idh-mutant anaplastic astrocytoma 33.1 MGMT IDH2 ATRX
2 idh-wildtype anaplastic astrocytoma 33.1 MGMT IDH2 ATRX
3 astrocytoma, idh-mutant, grade 4 32.5 PDGFRA MGMT IDH2 ATRX
4 high grade glioma 31.5 VEGFA TP53 PTEN PDGFRA MGMT MDM2
5 glioblastoma 31.5 VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
6 brain cancer 31.3 VEGFA TP53 PTEN PDGFRA OLIG2 OLIG1
7 glioma 31.3 TP53 PTEN MGMT MDM2 IDH2 EGFR
8 malignant astrocytoma 31.2 VEGFA TP53 PTEN MGMT EGFR ATRX
9 high-grade astrocytoma 31.2 TP53 PTEN ATRX
10 oligoastrocytoma 31.2 MGMT IDH2 GFAP
11 neurofibromatosis, type i 31.0 TP53 PTEN PDGFRA EGFR CDKN2A
12 neurofibromatosis 31.0 VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
13 enchondromatosis, multiple, ollier type 30.9 TP53 IDH2 ATRX
14 bap1 tumor predisposition syndrome 30.9 TP53 PTEN EGFR CDKN2A CDK4
15 adenoma 30.9 TP53 MGMT CDKN2A CCND1
16 atypical teratoid rhabdoid tumor 30.9 TP53 OLIG2 GFAP EGFR CDKN2A CCND1
17 diffuse astrocytoma 30.8 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
18 inherited cancer-predisposing syndrome 30.8 TP53 PTEN EGFR CDKN2A CDK4
19 hydrocephalus 30.8 VEGFA TP53 PTEN GFAP
20 myelodysplastic syndrome 30.8 VEGFA TP53 PDGFRA IDH2 CDKN2B CDKN2A
21 pilocytic astrocytoma 30.7 TP73 TP53 PTEN PDGFRA OLIG2 MGMT
22 medulloblastoma 30.7 VEGFA TP73 TP53 PTEN PDGFRA OLIG2
23 meningioma, familial 30.7 VEGFA TP73 TP53 S100A5 PTEN OLIG2
24 low grade glioma 30.7 VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
25 leukemia, acute lymphoblastic 30.7 TP73 TP53 CDKN2B CDKN2A CDK4
26 anaplastic pleomorphic xanthoastrocytoma 30.6 OLIG2 MGMT ATRX
27 mismatch repair cancer syndrome 30.6 TP53 PTEN MGMT
28 plexiform neurofibroma 30.6 TP53 PDGFRA EGFR CDKN2A
29 choroid plexus cancer 30.6 TP53 OLIG2 GFAP ATRX
30 leukemia, chronic myeloid 30.6 VEGFA TP53 PTEN PDGFRA EGFR CDKN2B
31 pleomorphic xanthoastrocytoma 30.6 TP53 MGMT IDH2 CDKN2A ATRX
32 diffuse midline glioma, h3 k27m-mutant 30.6 TP53 PDGFRA OLIG2 MGMT ATRX
33 hemangioma 30.6 VEGFA TP53 PTEN EGFR CDKN2A
34 hemangioblastoma 30.6 VEGFA PDGFRA GFAP EGFR
35 oligodendroglioma 30.5 VEGFA TP73 TP53 PTEN PDGFRA OLIG2
36 neurofibroma 30.5 VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
37 paraganglioma 30.5 IDH2 GFAP EGFR CDKN2A CCND1 ATRX
38 gliomatosis cerebri 30.5 TP53 PTEN OLIG2 MGMT IDH2 GFAP
39 fanconi anemia, complementation group a 30.5 TP73 TP53 PTEN MDM2 CDKN2A ATRX
40 lynch syndrome 30.5 VEGFA TP53 PTEN MGMT EGFR CDKN2A
41 li-fraumeni syndrome 30.5 TP53 PTEN MDM2 EGFR CDKN2B CDKN2A
42 skin disease 30.5 VEGFA TP53 PTEN EGFR CDKN2A CCND1
43 spinal cord astrocytoma 30.5 IDH2 ATRX
44 rhabdomyosarcoma 2 30.4 TP53 MDM2 CDK4
45 idh-wildtype glioblastoma 30.4 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
46 gliosarcoma 30.4 VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
47 renal cell carcinoma, nonpapillary 30.4 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
48 mixed glioma 30.4 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
49 melanoma 30.4 VEGFA TP53 PTEN PDGFRA MGMT MDM2
50 anaplastic oligodendroglioma 30.4 VEGFA TP53 PTEN PDGFRA OLIG2 OLIG1

Graphical network of the top 20 diseases related to Anaplastic Astrocytoma:



Diseases related to Anaplastic Astrocytoma

Symptoms & Phenotypes for Anaplastic Astrocytoma

UMLS symptoms related to Anaplastic Astrocytoma:


headache; seizures; motor manifestations; sensory manifestations

GenomeRNAi Phenotypes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
2 no effect GR00402-S-2 10.15 ATRX CDK4 CDKN2A CDKN2B DMBT1 EGFR
3 Reduced mammosphere formation GR00396-S 9.56 ATRX CCND1 CDK4 EGFR IDH2 MCM3
4 Decreased viability in pancreas lineage GR00235-A 9.16 CCND1 TP53

MGI Mouse Phenotypes related to Anaplastic Astrocytoma:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.52 CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
2 nervous system MP:0003631 10.5 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
3 homeostasis/metabolism MP:0005376 10.47 CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
4 cellular MP:0005384 10.45 ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
5 growth/size/body region MP:0005378 10.43 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
6 endocrine/exocrine gland MP:0005379 10.36 CCND1 CDK4 CDKN2A CDKN2B EGFR MCM3
7 normal MP:0002873 10.31 CCND1 CDK4 EGFR GFAP MDM2 PDGFRA
8 embryo MP:0005380 10.31 ATRX CDK4 CDKN2A DMBT1 EGFR MCM3
9 digestive/alimentary MP:0005381 10.3 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
10 cardiovascular system MP:0005385 10.29 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
11 muscle MP:0005369 10.28 CDK4 CDKN2A EGFR GFAP MDM2 OLIG2
12 immune system MP:0005387 10.28 CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
13 behavior/neurological MP:0005386 10.27 ATRX CCND1 CDK4 CDKN2A GFAP MDM2
14 no phenotypic analysis MP:0003012 10.26 CDKN2A CDKN2B EGFR MDM2 MGMT OLIG2
15 renal/urinary system MP:0005367 10.24 CDK4 CDKN2B DMBT1 EGFR MDM2 PDGFRA
16 liver/biliary system MP:0005370 10.18 CDK4 CDKN2A EGFR MCM3 MDM2 PTEN
17 pigmentation MP:0001186 10.17 CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
18 reproductive system MP:0005389 10.15 ATRX CCND1 CDK4 CDKN2A CDKN2B EGFR
19 craniofacial MP:0005382 10.11 CCND1 CDK4 EGFR MDM2 PDGFRA TP53
20 respiratory system MP:0005388 10.1 CCND1 CDKN2A EGFR MGMT OLIG2 PDGFRA
21 skeleton MP:0005390 10.1 CCND1 CDK4 CDKN2A EGFR IDH2 MDM2
22 vision/eye MP:0005391 10 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
23 hematopoietic system MP:0005397 9.97 CCND1 CDK4 CDKN2A CDKN2B EGFR IDH2
24 mortality/aging MP:0010768 9.91 ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
25 integument MP:0010771 9.4 CCND1 CDK4 CDKN2A CDKN2B EGFR MCM3

Drugs & Therapeutics for Anaplastic Astrocytoma

Drugs for Anaplastic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
2
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
3
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
5
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
6
Eflornithine Approved, Withdrawn Phase 3 70052-12-9 3009
7
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
8
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
9
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
10
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
11
Semustine Experimental, Investigational Phase 3 13909-09-6 5198
12
Trabedersen Investigational Phase 3 925681-61-4
13 Interferon-alpha Phase 3
14 Anticonvulsants Phase 3
15 Pharmaceutical Solutions Phase 3
16 Psychotropic Drugs Phase 3
17 Antiprotozoal Agents Phase 3
18 Antiparasitic Agents Phase 3
19 Immunoglobulin G Phase 2, Phase 3
20 Endothelial Growth Factors Phase 2, Phase 3
21 Antineoplastic Agents, Immunological Phase 2, Phase 3
22 Mitogens Phase 3
23 Angiogenesis Inhibitors Phase 2, Phase 3
24
Iodine Approved, Investigational Phase 2 7553-56-2 807
25
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
26
Carmustine Approved, Investigational Phase 2 154-93-8 2578
27
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
28
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
31
Aflibercept Approved Phase 2 862111-32-8 124490314
32
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908
33
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
34
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
35
Mercaptopurine Approved Phase 2 50-44-2 667490
36
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
37
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
38
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
39
Etoposide Approved Phase 2 33419-42-0 36462
40
Valaciclovir Approved, Investigational Phase 1, Phase 2 124832-27-5, 124832-26-4 60773 135398742
41
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
42
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
43
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
44
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
45
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
46
Sorbitol Approved, Investigational Phase 1, Phase 2 69-65-8, 50-70-4 453 6251 5780
47
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
48
Cetuximab Approved Phase 1, Phase 2 205923-56-4
49
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
4 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
5 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
6 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
7 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
8 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
9 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
10 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
11 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
12 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Active, not recruiting NCT02796261 Phase 3 Eflornithine;Lomustine
13 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
14 Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
15 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Terminated NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
16 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
17 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
18 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
19 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
20 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
21 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma Completed NCT00783393 Phase 2 Temozolomide
22 A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
23 A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
24 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
25 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme Completed NCT00606008 Phase 2 Sunitinib Malate
26 Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
27 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
28 A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
29 Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00301418 Phase 1, Phase 2 Erlotinib
30 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
31 BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy Completed NCT00115440 Phase 1, Phase 2
32 Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT02942264 Phase 1, Phase 2 Zotiraciclib (TG02);Temozolomide (TMZ)
33 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Completed NCT00679354 Phase 2 cilengitide
34 Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week Completed NCT00431561 Phase 2 AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV
35 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
36 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
37 A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
38 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
39 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
40 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
41 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
42 Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study Completed NCT00041587 Phase 1, Phase 2 IL13-PE38QQR
43 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Completed NCT00879437 Phase 2 Valproic acid;Bevacizumab
44 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
45 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
46 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
47 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
48 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
49 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
50 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study Completed NCT00024570 Phase 1, Phase 2 IL13-PE38QQR

Search NIH Clinical Center for Anaplastic Astrocytoma

Genetic Tests for Anaplastic Astrocytoma

Genetic tests related to Anaplastic Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma, Anaplastic 28

Anatomical Context for Anaplastic Astrocytoma

Organs/tissues related to Anaplastic Astrocytoma:

MalaCards : Brain, Spinal Cord, Eye, Bone Marrow, Endothelial, Bone, Breast

Publications for Anaplastic Astrocytoma

Articles related to Anaplastic Astrocytoma:

(show top 50) (show all 2274)
# Title Authors PMID Year
1
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. 53 62
20090216 2010
2
Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. 53 62
19876867 2009
3
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. 53 62
19512898 2009
4
Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. 53 62
18795327 2009
5
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 53 62
19346643 2009
6
Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. 53 62
19151620 2009
7
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 53 62
19657395 2009
8
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. 53 62
18945611 2009
9
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. 53 62
18974115 2008
10
PTEN signaling pathways in glioblastoma. 53 62
18836294 2008
11
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 53 62
17998256 2007
12
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. 53 62
17404569 2007
13
Concurrent EGFR amplification and TP-53 mutation in glioblastomas. 53 62
17907599 2007
14
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. 53 62
17721049 2007
15
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 53 62
17679463 2007
16
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 53 62
17415208 2007
17
Molecular pathogenesis of pediatric astrocytic tumors. 53 62
17327574 2007
18
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. 53 62
16818615 2006
19
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. 53 62
16849758 2006
20
Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. 53 62
16614947 2006
21
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. 53 62
16618782 2006
22
Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. 53 62
16150117 2005
23
Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. 53 62
16055749 2005
24
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. 53 62
15994925 2005
25
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. 53 62
15973775 2005
26
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. 53 62
16030116 2005
27
Apoptosis and proliferation: correlation with p53 in astrocytic tumours. 53 62
15981097 2005
28
Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. 53 62
15671553 2005
29
Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. 53 62
15659871 2004
30
Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. 53 62
12968803 2003
31
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. 53 62
12939468 2003
32
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. 53 62
12777082 2003
33
Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. 53 62
12700122 2003
34
Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. 53 62
12702589 2003
35
Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. 53 62
15679305 2003
36
Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression. 53 62
12389885 2002
37
Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. 53 62
11958417 2002
38
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 53 62
11683943 2001
39
Elevated levels of cathepsin B in human glioblastoma cell lines. 53 62
11494030 2001
40
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. 53 62
11504770 2001
41
[A case of glioblastoma associated with dissemination, secondary to intratumoral hemorrhage]. 53 62
11554096 2001
42
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. 53 62
11431323 2001
43
Characterisation of molecular alterations in microdissected archival gliomas. 53 62
11355303 2001
44
Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. 53 62
11277408 2001
45
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. 53 62
11234878 2001
46
Promoter hypermethylation of the RB1 gene in glioblastomas. 53 62
11204276 2001
47
Regulation of the uPA gene in various grades of human glioma cells. 53 62
11115541 2001
48
Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. 53 62
11517976 2001
49
Functional evaluation of p53 and PTEN gene mutations in gliomas. 53 62
11051241 2000
50
Molecular genetic analysis of archival gliomas using diagnostic smears. 53 62
11054184 2000

Variations for Anaplastic Astrocytoma

ClinVar genetic disease variations for Anaplastic Astrocytoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Pathogenic
12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
2 ATRX NM_000489.6(ATRX):c.5579A>G (p.Asn1860Ser) SNV Pathogenic
11724 rs45439799 GRCh37: X:76856021-76856021
GRCh38: X:77600552-77600552
3 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776

Expression for Anaplastic Astrocytoma

Search GEO for disease gene expression data for Anaplastic Astrocytoma.

Pathways for Anaplastic Astrocytoma

Pathways related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CCND1 CDK4 CDKN2A CDKN2B EGFR MDM2
2
Show member pathways
13.83 ATRX CCND1 CDK4 CDKN2A EGFR MDM2
3 13.8 CCND1 CDK4 CDKN2B EGFR GFAP MDM2
4
Show member pathways
13.73 VEGFA TP53 PDGFRA MDM2 EGFR CDKN2B
5
Show member pathways
13.54 ATRX CCND1 CDK4 CDKN2A CDKN2B MCM3
6
Show member pathways
13.45 CCND1 CDK4 CDKN2A CDKN2B EGFR MDM2
7
Show member pathways
12.97 CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
8
Show member pathways
12.95 VEGFA TP73 TP53 PTEN MDM2 EGFR
9
Show member pathways
12.76 TP53 MDM2 CDKN2B CDKN2A CDK4
10
Show member pathways
12.66 VEGFA TP53 PTEN MDM2 EGFR CDKN2A
11
Show member pathways
12.64 CCND1 CDK4 MDM2 MGMT TP53
12
Show member pathways
12.54 CDKN2B CDKN2A CDK4 CCND1 ATRX
13
Show member pathways
12.52 MCM3 CDKN2B CDKN2A CDK4 CCND1
14
Show member pathways
12.45 TP53 PDGFRA MDM2 EGFR
15
Show member pathways
12.43 TP53 PTEN PDGFRA MDM2 EGFR CDK4
16 12.42 CCND1 CDK4 CDKN2A EGFR MDM2 PDGFRA
17
Show member pathways
12.39 CDKN2B CDKN2A CDK4 CCND1
18 12.39 TP73 TP53 MGMT MDM2 MCM3 CDKN2A
19 12.33 VEGFA PTEN PDGFRA EGFR CCND1
20
Show member pathways
12.29 TP53 PTEN MDM2 CCND1
21
Show member pathways
12.26 TP53 PTEN MDM2 CDK4 CCND1
22 12.22 VEGFA TP53 EGFR CCND1
23
Show member pathways
12.22 CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
24
Show member pathways
12.2 TP53 PTEN CDKN2A CDK4 CCND1
25
Show member pathways
12.18 CCND1 CDK4 CDKN2A CDKN2B MCM3 MDM2
26
Show member pathways
12.16 PTEN MDM2 EGFR CCND1
27
Show member pathways
12.16 TP53 CDKN2B CDKN2A CDK4 CCND1
28
Show member pathways
12.15 TP53 MDM2 CDK4 CCND1
29 12.13 TP53 PTEN PDGFRA EGFR
30 12.1 EGFR MDM2 PTEN TP53 TP73
31 12.05 TP53 GFAP EGFR CDK4 CCND1
32 12.02 VEGFA EGFR CDKN2A CCND1
33 11.98 TP53 PTEN MDM2 CDKN2A
34 11.98 TP73 TP53 PTEN MDM2 CCND1
35 11.98 VEGFA TP53 PTEN MDM2 EGFR CDK4
36
Show member pathways
11.95 TP73 TP53 MDM2 CDKN2A
37 11.95 TP53 PTEN CDKN2B CDK4 CCND1
38 11.88 EGFR PDGFRA PTEN VEGFA
39 11.88 TP53 MDM2 MCM3 CDK4 CCND1
40
Show member pathways
11.87 PDGFRA EGFR CCND1
41
Show member pathways
11.83 TP73 TP53 MDM2
42 11.83 VEGFA PDGFRA OLIG2 OLIG1 GFAP
43
Show member pathways
11.79 TP53 MDM2 CDKN2A
44 11.78 TP53 PTEN CDKN2A CCND1
45
Show member pathways
11.75 VEGFA EGFR CCND1
46 11.75 VEGFA TP53 MDM2 CDKN2A
47 11.72 CDKN2A MCM3 TP73
48 11.7 TP53 PTEN ATRX
49 11.69 TP53 CDK4 CCND1
50
Show member pathways
11.69 TP53 PTEN MDM2 CCND1

GO Terms for Anaplastic Astrocytoma

Cellular components related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin D1-CDK4 complex GO:0097128 8.92 CDK4 CCND1

Biological processes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.26 VEGFA TP53 PTEN MGMT MDM2 EGFR
2 response to xenobiotic stimulus GO:0009410 10.11 TP73 TP53 MGMT CDK4 CCND1
3 cellular response to hypoxia GO:0071456 10.08 MDM2 PTEN TP53 VEGFA
4 positive regulation of cell population proliferation GO:0008284 9.97 CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
5 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.88 PTEN CDKN2B CDKN2A
6 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.8 VEGFA TP53
7 cellular response to actinomycin D GO:0072717 9.73 TP53 MDM2
8 positive regulation of phosphorylation GO:0042327 9.67 EGFR PDGFRA VEGFA
9 cell cycle GO:0007049 9.65 TP73 TP53 MCM3 CDKN2B CDKN2A CDK4
10 response to UV-A GO:0070141 9.62 EGFR CCND1
11 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.56 VEGFA PDGFRA
12 positive regulation of miRNA maturation GO:1903800 9.51 TP53 EGFR
13 regulation of cell cycle GO:0051726 9.4 TP73 TP53 PTEN MDM2 CDKN2A CDK4

Molecular functions related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.93 TP73 TP53 PTEN CDKN2B CDKN2A CCND1
2 disordered domain specific binding GO:0097718 9.35 TP53 MDM2 CDKN2A
3 kinase activity GO:0016301 9.1 PDGFRA EGFR CDKN2B CDKN2A CDK4 CCND1

Sources for Anaplastic Astrocytoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....